Andecaliximab

Andecaliximab
Monoclonal antibody
Type	?
Source	Chimeric (mouse/human)
Target	gelatinase B
Clinical data
Other names	GS-5745
ATC code	none;
Identifiers
CAS Number	1518996-49-0;
ChemSpider	none;
UNII	571045EIM4;
KEGG	D11262;
Chemical and physical data
Formula	C6396H9868N1680O2010S46
Molar mass	143933.81 g·mol−1

Andecaliximab (INN;^[1] development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.

This drug was developed by Gilead Sciences, Inc.^[2]

Phase II and phase III trials for gastric cancer or gastroesophageal junction adenocarcinoma completed in 2019.

References

^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Andecaliximab, American Medical Association.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[WHOList115-1] World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).

[2] Statement On A Nonproprietary Name Adopted By The USAN Council - Andecaliximab, American Medical Association.

[1]

[2]